Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Takeda today announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application resubmission for the investigational subcutaneous administration of... | April 27, 2023